EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)
Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
2 findings from 1 review
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Monoclonal antibody + chemoradiotherapy vs chemoradiotherapy aloneHR 1.08 [0.89, 1.32]1 study · 891 participantsGRADE not reported
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes24 to 70 months · Monoclonal antibody + radiotherapy vs radiotherapy aloneHR 0.70 [0.54, 0.91]1 study · 424 participantsGRADE not reported